Journal article
Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children
Z Liu, M Julsgaard, X Zhu, J Martin, ML Barclay, N Cranswick, PR Gibson, RB Gearry, J Van Der Giessen, SJ Connor, O Rosella, A Grosen, C Toong, E Flanagan, JW Wieringa, C Janneke Van Der Woude, SJ Bell, S Kanis, J Fallingborg, CL Hvas Show all
Journal of Crohn S and Colitis | Published : 2022
Abstract
Background and Aims: For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy. Methods: We prospectively followed in utero infliximab/adalimumab-exposed infants of mothers with inflammatory bowel disease across four countries between 2011 and 2018. Infants with a detectable anti-TNF umbilical-cord level and at least one other blood sample during the first year of ..
View full abstractGrants
Funding Acknowledgements
The study was supported by unrestricted grants by the Health Research Fund of Central Denmark Region, the Colitis-Crohn Organization Denmark, and the A.P. Moeller Foundation of the Advancement of Medical Science, the Department of Gastroenterology at Monash University, and Alfred Hospital [Melbourne, Victoria, Australia]. The external funders had no involvement in any aspect of the study and writing of the report.